PMID- 28833192
OWN - NLM
STAT- MEDLINE
DCOM- 20180629
LR  - 20220328
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
VI  - 57
IP  - 12
DP  - 2017 Dec
TI  - Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived 
      Neurotrophic Factor, and Tumor Necrosis Factor-alpha Level in Patients With Major 
      Depressive Disorder With Severe Depression.
PG  - 1519-1526
LID - 10.1002/jcph.963 [doi]
AB  - Evidence suggests that neurotrophic factors, inflammatory markers, and circadian 
      rhythm dysfunctions could be involved in pathophysiology of major depressive 
      disorder. This study evaluated the efficacy and tolerability of agomelatine, a 
      melatonergic drug, and fluoxetine (positive comparator) and their effect on serum 
      brain-derived neurotrophic factor (BDNF) and tumor necrosis factor (TNF)-alpha level 
      in patients having major depressive disorder with severe depression. In the 
      present study, we chose TNF-alpha and BDNF because reduction of TNF-alpha and rise in 
      BDNF levels are linked with improvement in major depressive disorder. Patients 
      with Hamilton Rating Scale for Depression (HAM-D) score >/=25 were treated with 
      agomelatine or fluoxetine and followed up for 12 weeks. In the agomelatine group, 
      the HAM-D score, BDNF level, and TNF-alpha level at the start of treatment were 
      31.1 +/- 1.88 ng/mL, 2.44 +/- 0.38 ng/mL, and 512.5 +/- 86.2 pg/mL, respectively, which 
      significantly changed to 13.67 +/- 2.22 ng/mL, 2.87 +/- 0.44 ng/mL, and 
      391.64 +/- 104.8 pg/mL, respectively (P < .05 for all 3 measures), at 12 weeks. In 
      the fluoxetine group, the HAM-D score, BDNF level, and TNF-alpha level at the start 
      of treatment were 30.83 +/- 2.60 ng/mL, 2.54 +/- 0.37 ng/mL, and 554.14 +/- 46.8 pg/mL, 
      respectively, which significantly changed to 13.67 +/- 1.79 ng/mL, 3.07 +/- 0.33 
      ng/mL, and 484.15 +/- 49.9 pg/mL, respectively (P < .05 for all 3 measures) at 12 
      weeks. The BDNF level was significantly increased posttreatment with both drugs, 
      and TNF-alpha level fell significantly more with agomelatine compared to fluoxetine. 
      Thus, chronic neuroinflammatory biomarkers contribute to circuitry dysregulation 
      in depression. Trophic factors repair dysfunctional circuits in depression. Both 
      treatments were found to be safe and well tolerated.
CI  - (c) 2017, The American College of Clinical Pharmacology.
FAU - Gupta, Keshav
AU  - Gupta K
AD  - Department of Pharmacology, University College of Medical Sciences & Guru Teg 
      Bahadur Hospital , New Delhi, India.
FAU - Gupta, Rachna
AU  - Gupta R
AUID- ORCID: 0000-0002-3377-9626
AD  - Department of Pharmacology, University College of Medical Sciences & Guru Teg 
      Bahadur Hospital , New Delhi, India.
FAU - Bhatia, M S
AU  - Bhatia MS
AD  - Department of Psychiatry, University College of Medical Sciences & Guru Teg 
      Bahadur Hospital, New Delhi, India.
FAU - Tripathi, A K
AU  - Tripathi AK
AD  - Department of Biochemistry, University College of Medical Sciences & Guru Teg 
      Bahadur Hospital, New Delhi, India.
FAU - Gupta, Lalit K
AU  - Gupta LK
AD  - Department of Pharmacology, Lady Hardinge Medical College & Smt. S.K. Hospital, 
      New Delhi, India.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170817
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Acetamides)
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Hypnotics and Sedatives)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 137R1N49AD (agomelatine)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Acetamides/administration & dosage/*therapeutic use
MH  - Adult
MH  - Antidepressive Agents/administration & dosage/therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood/metabolism
MH  - Depressive Disorder, Major/*drug therapy
MH  - Female
MH  - Fluoxetine/therapeutic use
MH  - Humans
MH  - Hypnotics and Sedatives/administration & dosage/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Psychiatric Status Rating Scales
MH  - Tumor Necrosis Factor-alpha/*blood/metabolism
OTO - NOTNLM
OT  - MDD
OT  - SSRI
OT  - cytokine
OT  - depression
OT  - inflammation
OT  - melatonin
EDAT- 2017/08/24 06:00
MHDA- 2018/06/30 06:00
CRDT- 2017/08/24 06:00
PHST- 2017/03/21 00:00 [received]
PHST- 2017/05/17 00:00 [accepted]
PHST- 2017/08/24 06:00 [pubmed]
PHST- 2018/06/30 06:00 [medline]
PHST- 2017/08/24 06:00 [entrez]
AID - 10.1002/jcph.963 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2017 Dec;57(12):1519-1526. doi: 10.1002/jcph.963. Epub 2017 Aug 
      17.